Results 21 to 30 of about 6,410,935 (343)

Screening of Natural Products Inhibitors of SARS-CoV-2 Entry

Molecules, 2022
The COVID-19 pandemic has led to the search for new molecules with antiviral activity against SARS-CoV-2. The entry of the virus into the cell is one of the main targets for inhibiting SARS-CoV-2 infection. Natural products are an important source of new
Pamela González-Maldonado, Nelson Alvarenga, Alberto Burgos-Edwards, Ma. Eugenia Flores-Giubi, Javier E. Barúa, Ma. Cristina Romero-Rodríguez, Ricardo Soto-Rifo, Fernando Valiente-Echeverría, Patricia Langjahr, Guadalupe Cantero-González, Pablo H. Sotelo   +10 more
doaj   +1 more source

Phenothiazines Inhibit SARS-CoV-2 Entry through Targeting Spike Protein

Viruses, 2023
Novel coronavirus disease 2019 (COVID-19), a respiratory disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has brought an unprecedented public health crisis and continues to threaten humanity due to the persistent emergence ...
Taizhen Liang, Shiqi Xiao, Ziyao Wu, Xi Lv, Sen Liu, Meilin Hu, Guojie Li, Peiwen Li, Xiancai Ma   +8 more
doaj   +1 more source

Composition and Orientation of the Core Region of Novel HIV-1 Entry Inhibitors Influences Metabolic Stability

Molecules, 2020
Fostemsavir/temsavir is an investigational HIV-1 entry inhibitor currently in late-stage clinical trials. Although it holds promise to be a first-in-class Env-targeted entry inhibitor for the clinic, issues with bioavailability relegate its use to ...
Rama Karadsheh, Megan E. Meuser, Simon Cocklin   +2 more
doaj   +1 more source

A Palmitic Acid-Conjugated, Peptide-Based pan-CoV Fusion Inhibitor Potently Inhibits Infection of SARS-CoV-2 Omicron and Other Variants of Concern

Viruses, 2022
Our previous studies have shown that cholesterol-conjugated, peptide-based pan-coronavirus (CoV) fusion inhibitors can potently inhibit human CoV infection. However, only palmitic acid (C16)-based lipopeptide drugs have been tested clinically, suggesting
Qiaoshuai Lan, Jasper Fuk-Woo Chan, Wei Xu, Lijue Wang, Fanke Jiao, Guangxu Zhang, Jing Pu, Jie Zhou, Shuai Xia, Lu Lu, Kwok-Yung Yuen, Shibo Jiang, Qian Wang   +12 more
doaj   +1 more source

Hepatitis D Virus Entry Inhibitors Based on Repurposing Intestinal Bile Acid Reabsorption Inhibitors

Viruses, 2021
Identification of Na+/taurocholate co-transporting polypeptide (NTCP) as high-affinity hepatic entry receptor for the Hepatitis B and D viruses (HBV/HDV) opened the field for target-based development of cell-entry inhibitors. However, most of the HBV/HDV
Michael Kirstgen, Kira Alessandra Alicia Theresa Lowjaga, Simon Franz Müller, Nora Goldmann, Felix Lehmann, Dieter Glebe, Karl-Heinz Baringhaus, Joachim Geyer   +7 more
doaj   +1 more source

The entry of entry inhibitors: A fusion of science and medicine [PDF]

Proceedings of the National Academy of Sciences, 2003
For HIV-1 to enter a cell, its envelope protein (Env) must sequentially engage CD4 and a chemokine coreceptor, triggering conformational changes in Env that ultimately lead to fusion between the viral and host cell membranes. Each step of the virus entry pathway is a potential target for novel antiviral agents termed entry inhibitors.
John P, Moore, Robert W, Doms
openaire   +2 more sources

Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19

Viruses, 2022
An escalating pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has severely impacted global health. There is a severe lack of specific treatment options for diseases caused by SARS-CoV-2.
Junyuan Cao, Yang Liu, Minmin Zhou, Siqi Dong, Yuxia Hou, Xiaoying Jia, Xiaohao Lan, Yueli Zhang, Jiao Guo, Gengfu Xiao, Wei Wang   +10 more
doaj   +1 more source

HIV-1 Entry and Prospects for Protecting against Infection

Microorganisms, 2021
Human Immunodeficiency Virus type-1 (HIV-1) establishes a latent viral reservoir soon after infection, which poses a major challenge for drug treatment and curative strategies. Many efforts are therefore focused on blocking infection.
Jean-François Bruxelle, Nino Trattnig, Marianne W. Mureithi, Elise Landais, Ralph Pantophlet   +4 more
doaj   +1 more source

Screening and Identification of Lujo Virus Entry Inhibitors From an Food and Drug Administration-Approved Drugs Library

Frontiers in Microbiology, 2021
Lujo virus (LUJV) belongs to the Old World (OW) genus Mammarenavirus (family Arenaviridae). It is categorized as a biosafety level (BSL) 4 agent. Currently, there are no U.S.
Junyuan Cao, Junyuan Cao, Siqi Dong, Siqi Dong, Yang Liu, Minmin Zhou, Minmin Zhou, Jiao Guo, Jiao Guo, Xiaoying Jia, Xiaoying Jia, Yueli Zhang, Yueli Zhang, Yuxia Hou, Yuxia Hou, Ming Tian, Gengfu Xiao, Gengfu Xiao, Wei Wang, Wei Wang   +19 more
doaj   +1 more source

Customizably designed multibodies neutralize SARS-CoV-2 in a variant-insensitive manner

Frontiers in Immunology, 2023
The COVID-19 pandemic evolves constantly, requiring adaptable solutions to combat emerging SARS-CoV-2 variants. To address this, we created a pentameric scaffold based on a mammalian protein, which can be customized with up to 10 protein binding modules.
Cecilia Abreu, Claudia Ortega, Natalia Olivero-Deibe, Federico Carrión, Aracelly Gaete-Argel, Aracelly Gaete-Argel, Fernando Valiente-Echeverría, Fernando Valiente-Echeverría, Ricardo Soto-Rifo, Ricardo Soto-Rifo, Rafaela Milan Bonotto, Alessandro Marcello, Sergio Pantano   +12 more
doaj   +1 more source